PL2146745T3 - Pięcioswoiste przeciwciało - Google Patents

Pięcioswoiste przeciwciało

Info

Publication number: PL2146745T3
Authority: PL; Poland
Prior art keywords: penta; specific antibody; antibody; specific
Prior art date: 2007-04-17

Application number

PL08745931T

Other languages

English (en)

Inventor

Stephanie Jane Clegg

Eric Dobrzynski

Jonathan H Ellis

Volker Germaschewski

Alexis Paul Godillot

Zdenka Ludmila Jonak

Alan P Lewis

John R White

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-17

Filing date

2008-04-16

Publication date

2015-11-30

2008-04-16 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2015-11-30 Publication of PL2146745T3 publication Critical patent/PL2146745T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Diabetes (AREA)
Neurology (AREA)

PL08745931T 2007-04-17 2008-04-16 Pięcioswoiste przeciwciało PL2146745T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US91222907P	2007-04-17	2007-04-17
US4413208P	2008-04-11	2008-04-11
PCT/US2008/060424 WO2008130969A2 (en)	2007-04-17	2008-04-16	Novel compounds
EP08745931.9A EP2146745B1 (en)	2007-04-17	2008-04-16	penta-specific antibody

Publications (1)

Publication Number	Publication Date
PL2146745T3 true PL2146745T3 (pl)	2015-11-30

Family

ID=39872910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08745931T PL2146745T3 (pl)	2007-04-17	2008-04-16	Pięcioswoiste przeciwciało

Country Status (29)

Country	Link
US (3)	US8496932B2 (pl)
EP (1)	EP2146745B1 (pl)
JP (1)	JP5441885B2 (pl)
KR (1)	KR101560841B1 (pl)
CN (1)	CN101687035B (pl)
AU (1)	AU2008243049B2 (pl)
BR (1)	BRPI0810250A8 (pl)
CA (1)	CA2684626C (pl)
CL (1)	CL2008001071A1 (pl)
CO (1)	CO6251323A2 (pl)
CR (1)	CR11116A (pl)
CY (1)	CY1116671T1 (pl)
DK (1)	DK2146745T3 (pl)
DO (1)	DOP2009000236A (pl)
EA (1)	EA024621B1 (pl)
ES (1)	ES2547475T3 (pl)
HR (1)	HRP20150937T1 (pl)
HU (1)	HUE027584T2 (pl)
IL (1)	IL201440A (pl)
MA (1)	MA31310B1 (pl)
MX (1)	MX2009011153A (pl)
MY (1)	MY150525A (pl)
NZ (1)	NZ580239A (pl)
PE (1)	PE20090302A1 (pl)
PL (1)	PL2146745T3 (pl)
PT (1)	PT2146745E (pl)
SI (1)	SI2146745T1 (pl)
TW (1)	TWI473815B (pl)
WO (1)	WO2008130969A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
ES2595638T3 (es)	2007-09-26	2017-01-02	Chugai Seiyaku Kabushiki Kaisha	Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko)	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP6018917B2 (ja)	2009-12-07	2016-11-02	デシミューンセラピューティクス，インコーポレイテッド	抗炎症抗体およびその使用
US20120315267A1 (en) *	2010-02-09	2012-12-13	Glaxosmithkline Llc	Novel uses
EP2647706B1 (en)	2010-11-30	2023-05-17	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2013166099A1 (en)	2012-05-01	2013-11-07	Glaxosmithkline Llc	Novel antibodies
WO2014030750A1 (ja)	2012-08-24	2014-02-27	中外製薬株式会社	マウスFcγRII特異的Fc抗体
SG10201709559PA (en)	2012-08-24	2017-12-28	Chugai Pharmaceutical Co Ltd	Fcγriib-specific fc region variant
WO2014165115A1 (en)	2013-03-12	2014-10-09	Decimmune Therapeutics, Inc.	Humanized anti-n2 antibodies
TWI612059B (zh) *	2013-03-15	2018-01-21	美國禮來大藥廠	泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
US9290570B2 (en)	2013-03-15	2016-03-22	Eli Lilly And Company	Pan-ELR+ CXC Chemokine Antibodies
CN105246914B (zh)	2013-04-02	2021-08-27	中外制药株式会社	Fc区变体
EP2796875B8 (en) *	2013-04-23	2020-11-25	Albert-Ludwigs-Universität Freiburg	Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
KR20160021125A (ko)	2013-05-17	2016-02-24	쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스)	항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko)	2015-02-05	2023-11-23	추가이 세이야쿠 가부시키가이샤	이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
EP3494991A4 (en)	2016-08-05	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3684811A2 (en) *	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multiple specificity binders of cxc chemokines and uses thereof
US11525002B2 (en)	2017-10-11	2022-12-13	Board Of Regents, The University Of Texas System	Human PD-L1 antibodies and methods of use therefor
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
SG11202009258RA (en) *	2018-03-23	2020-10-29	Univ Texas	Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN119101158A (zh)	2018-03-23	2024-12-10	得克萨斯州大学系统董事会	人pd-l2抗体及其使用方法
EP4501355A3 (en)	2018-03-23	2025-04-30	Board Of Regents, The University Of Texas System	Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
US11827709B2 (en) *	2019-12-05	2023-11-28	Seagen Inc.	Anti-AVB6 antibodies and antibody-drug conjugates
TW202206457A (zh) *	2020-04-24	2022-02-16	美商美國禮來大藥廠	用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) *	2020-09-14	2022-03-17	National Yang-Ming University	Method for preventing or treating peripheral arterial occlusive disease
WO2026060205A1 (en)	2024-09-13	2026-03-19	Eli Lilly And Company	PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE913192A1 (en) *	1990-09-12	1992-02-25	Scripps Research Inst	Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) *	1993-09-14	2002-09-10	Chiron Corporation	IL8 inhibitors
PT833911E (pt) *	1995-06-07	2004-09-30	Ortho Mcneil Pharm Inc	Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
AR030753A1 (es) *	2000-09-25	2003-09-03	Smithkline Beecham Corp	Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
PL366307A1 (pl) *	2000-10-13	2005-01-24	Biogen, Inc.	Humanizowane przeciwciała anty-LT-beta-R
WO2002088185A2 (en)	2001-04-26	2002-11-07	Dakocytomation Denmark A/S	Pan-specific monoclonal antibody
US20040022726A1 (en) *	2002-06-03	2004-02-05	Goldenberg David M.	Methods and compositions for intravesical therapy of bladder cancer
NZ541050A (en) *	2002-12-16	2010-06-25	Genmab As	Human monoclonal antibodies against interleukin 8 (IL-8)
JPWO2004060919A1 (ja) *	2002-12-26	2006-05-11	中外製薬株式会社	ヘテロ受容体に対するアゴニスト抗体
WO2005094882A1 (en) *	2004-03-03	2005-10-13	Millennium Pharmaceuticals, Inc.	Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2006074399A2 (en) *	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
JP2008541758A (ja) *	2005-06-02	2008-11-27	アストラゼネカエービー	Ｃｄ２０に対する抗体およびその使用
CA2612449A1 (en) *	2005-06-17	2006-12-28	Imclone Systems Incorporated	Receptor antagonists for treatment of metastatic bone cancer
GB0519398D0 (en) *	2005-09-23	2005-11-02	Antisoma Plc	Biological materials and uses thereof
WO2007056411A2 (en) *	2005-11-08	2007-05-18	Genentech, Inc.	Method of producing pan-specific antibodies
US8454960B2 (en) *	2008-01-03	2013-06-04	The Scripps Research Institute	Multispecific antibody targeting and multivalency through modular recognition domains

2008
- 2008-04-15 CL CL2008001071A patent/CL2008001071A1/es unknown
- 2008-04-16 EP EP08745931.9A patent/EP2146745B1/en not_active Not-in-force
- 2008-04-16 BR BRPI0810250A patent/BRPI0810250A8/pt not_active Application Discontinuation
- 2008-04-16 JP JP2010504204A patent/JP5441885B2/ja not_active Expired - Fee Related
- 2008-04-16 WO PCT/US2008/060424 patent/WO2008130969A2/en not_active Ceased
- 2008-04-16 PT PT87459319T patent/PT2146745E/pt unknown
- 2008-04-16 HU HUE08745931A patent/HUE027584T2/en unknown
- 2008-04-16 ES ES08745931.9T patent/ES2547475T3/es active Active
- 2008-04-16 MX MX2009011153A patent/MX2009011153A/es active IP Right Grant
- 2008-04-16 EA EA200970954A patent/EA024621B1/ru not_active IP Right Cessation
- 2008-04-16 NZ NZ580239A patent/NZ580239A/en not_active IP Right Cessation
- 2008-04-16 KR KR1020097023814A patent/KR101560841B1/ko not_active Expired - Fee Related
- 2008-04-16 SI SI200831489T patent/SI2146745T1/sl unknown
- 2008-04-16 HR HRP20150937TT patent/HRP20150937T1/hr unknown
- 2008-04-16 DK DK08745931.9T patent/DK2146745T3/en active
- 2008-04-16 PE PE2008000664A patent/PE20090302A1/es not_active Application Discontinuation
- 2008-04-16 MY MYPI20094336 patent/MY150525A/en unknown
- 2008-04-16 CA CA2684626A patent/CA2684626C/en not_active Expired - Fee Related
- 2008-04-16 US US12/596,262 patent/US8496932B2/en not_active Expired - Fee Related
- 2008-04-16 CN CN2008800205593A patent/CN101687035B/zh not_active Expired - Fee Related
- 2008-04-16 AU AU2008243049A patent/AU2008243049B2/en not_active Ceased
- 2008-04-16 PL PL08745931T patent/PL2146745T3/pl unknown
- 2008-04-16 TW TW97113788A patent/TWI473815B/zh not_active IP Right Cessation
- 2008-04-16 US US12/103,761 patent/US20080262203A1/en not_active Abandoned
2009
- 2009-10-08 DO DO2009000236A patent/DOP2009000236A/es unknown
- 2009-10-11 IL IL201440A patent/IL201440A/en not_active IP Right Cessation
- 2009-10-15 MA MA32279A patent/MA31310B1/fr unknown
- 2009-10-19 CO CO09116578A patent/CO6251323A2/es active IP Right Grant
- 2009-11-17 CR CR11116A patent/CR11116A/es unknown
2013
- 2013-06-26 US US13/927,352 patent/US8828384B2/en not_active Expired - Fee Related
2015
- 2015-09-01 CY CY20151100768T patent/CY1116671T1/el unknown

Also Published As

Publication number	Publication date
MX2009011153A (es)	2009-10-30
US8496932B2 (en)	2013-07-30
TW200906855A (en)	2009-02-16
AU2008243049A1 (en)	2008-10-30
IL201440A (en)	2016-08-31
SI2146745T1 (sl)	2015-10-30
EP2146745A4 (en)	2011-11-30
WO2008130969A2 (en)	2008-10-30
EA200970954A1 (ru)	2010-08-30
TWI473815B (zh)	2015-02-21
CN101687035B (zh)	2013-06-12
HK1136970A1 (en)	2010-07-16
NZ580239A (en)	2012-07-27
BRPI0810250A2 (pt)	2014-10-14
CA2684626C (en)	2014-11-04
PT2146745E (pt)	2015-10-14
HRP20150937T1 (hr)	2015-10-09
CR11116A (es)	2010-03-22
EA024621B1 (ru)	2016-10-31
JP5441885B2 (ja)	2014-03-12
CL2008001071A1 (es)	2009-05-22
HUE027584T2 (en)	2016-11-28
US20110229475A1 (en)	2011-09-22
CY1116671T1 (el)	2017-03-15
BRPI0810250A8 (pt)	2017-02-21
MA31310B1 (fr)	2010-04-01
DK2146745T3 (en)	2015-09-14
KR101560841B1 (ko)	2015-11-11
DOP2009000236A (es)	2009-11-15
ES2547475T3 (es)	2015-10-06
CO6251323A2 (es)	2011-02-21
AU2008243049B2 (en)	2011-04-21
EP2146745A2 (en)	2010-01-27
CA2684626A1 (en)	2008-10-30
MY150525A (en)	2014-01-30
US8828384B2 (en)	2014-09-09
KR20100020946A (ko)	2010-02-23
WO2008130969A3 (en)	2008-12-18
IL201440A0 (en)	2010-06-16
US20080262203A1 (en)	2008-10-23
JP2010524469A (ja)	2010-07-22
US20140010807A1 (en)	2014-01-09
CN101687035A (zh)	2010-03-31
EP2146745B1 (en)	2015-06-17
PE20090302A1 (es)	2009-04-03

Publication	Publication Date	Title
SI2146745T1 (sl)	2015-10-30	Penta-specifično protitelo
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
GB0708002D0 (en)	2007-06-06	Antibodies
SI2200700T1 (sl)	2016-04-29	Nova protitelesa
ZA201102119B (en)	2011-12-28	Improved antibody libraies
ZA201002422B (en)	2014-06-25	Modified antibody constant region
EP2077859A4 (en)	2010-11-24	ANTIBODY FORMULATION
ZA201003907B (en)	2011-03-30	Antibody formulation
GB0821100D0 (en)	2008-12-24	Antibodies
IL202648A0 (en)	2011-08-01	Antibody formulations
ZA200909107B (en)	2012-12-27	Antibody formulations
ZA201002275B (en)	2011-06-29	Il-23 antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
EP2173163A4 (en)	2010-12-08	ANTIBODY FORMULATIONS
GB0718737D0 (en)	2007-11-07	Antibodies
PT2011869E (pt)	2014-07-09	Novo anticorpo anti-cd98
ZA201006099B (en)	2012-01-25	Anti-tyrp1 antibodies
GB0702888D0 (en)	2007-03-28	Novel Antibodies
GB0615662D0 (en)	2006-09-13	Antibody
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
EP2167635A4 (en)	2010-06-30	ANTIBODY FORMULATIONS
GB0724185D0 (en)	2008-01-23	Antibodies
GB0817622D0 (en)	2008-11-05	Antibody